Sodium phenylbutyrate in Huntington's disease: A dose‐finding study
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose‐finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose‐escalation/de‐escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose‐response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well‐tolerated in human HD. © 2007 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., et al. (2001) · Nature · doi:10.1038/35099568 · Cited by 1,228 · cited 1×
“M, 41 yr 10 12 Nausea (1); headache (1) No F, 34 yr 10 12 Headache (1); gait instability (2) No M, 24 yr 10 12 Gait instability (1); increased depression (2) No F, 38 yr 13 15 Nausea (1) No M, 41 yr 11 15 Gait instability (1); vasovagal syncope w/blood draw (2) No M, 61 yr 5 15 No M, 42 yr 8 15 Nausea (1); diarrhea (1…”
Background
Cited by
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies
Urdinguio, R. G., Sanchez-Mut, J. V., & Esteller, M. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70262-5 · Cited by 582
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
“Unfortunately, a multicenter, double-blind, placebo-controlled clinical trial of 4PBA to determine safety and tolerability in HD, patients showed that its efficacy was very low, necessitating the use of high doses (Ebbel et al., 2010; Hogarth et al., 2007).”
BackgroundClinical and Experimental Applications of Sodium Phenylbutyrate
Iannitti, T., & Palmieri, B. (2011) · Drugs in R & D · doi:10.1007/bf03259725 · Cited by 270
The therapeutic potential of chemical chaperones in protein folding diseases
Cortez, L., & Sim, V. (2014) · Prion · doi:10.4161/pri.28938 · Cited by 254
Trials with ‘epigenetic’ drugs: An update
Nebbioso, A., Carafa, V., Benedetti, R., & Altucci, L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.004 · Cited by 237
“There are also two clinical trials with sodium phenylbutyrate: one in phase 2 for treatment of Huntington’s disease (Gardian et al., 2005; Hogarth et al., 2007) and one in phase 1e2 for amyotrophic lateral sclerosis (ALS) (Cudkowicz et al., 2009; Ryu et al., 2005).”
BackgroundHistone modifications, DNA methylation, and Schizophrenia
Gavin, D. P., & Sharma, R. P. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.10.010 · Cited by 121
Small molecule modulators of chromatin remodeling: from neurodevelopment to neurodegeneration
Jiang, D., Li, T., Guo, C., Tang, T.-S., & Liu, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00953-4 · Cited by 54
Metadata
- Authors
- Hogarth, P., Lovrecic, L., & Krainc, D.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2007-10-15
- Volume
- 22
- Issue
- 13
- Pages
- 1962-1964
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2129652328
- Cited by
- 89
- References
- 1
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.